# R21/Matrix-M in African Children Against Clinical Malaria

> **NCT04704830** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Oxford** · enrollment: 4800 (estimated)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** R21/Matrix-M
- **BIOLOGICAL:** Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

## Key facts

- **NCT ID:** NCT04704830
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-29
- **Primary completion:** 2023-03-21
- **Final completion:** 2028-04
- **Target enrollment:** 4800 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704830, "R21/Matrix-M in African Children Against Clinical Malaria". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04704830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*